Somalogic, Incorporated

Gilead Sciences, Inc.

Nexstar Pharmaceuticals, Inc.

Crestone, Inc.

Somalogic Operating Co., Inc.

Other

Merck Patent Gmbh

University of Colorado

Otsuka Pharmaceutical Company, Limited

Replidyne, Inc.

Nexstar Pharmaceuticlas, Inc.

Glead Sciences, Inc.

Nebojsa Janjic

Larry M Gold

Urs Ochsner

John C Rohloff

Amy D Gelinas

Paul J Schmidt

Thale Jarvis

Daniel W Drolet

Chi Zhang

Chandra Vargeese

Bharat Nathu Gawande

Sheela M Waugh

Louis S Green

Xicheng David Sun

Daniel J Schneider

Sarah A Strong

Diane Tasset

Joseph Guiles

Gary P Kirschenheuter

Wolfgang A Pieken

Jeff Carter

Michael Vrkljan

Andrew Stephens

Michael Willis

Jeffrey D Carter

Evaldas Katilius

Charles S McHenry

Albert Charles Gyorkos

Sumedha D Jayasena

Craig Tuerk

Paul G Schmidt

Dom Zichi

James M Bullard

Judy Ruckman

Catherine Fowler

John Rohloff

Sheri K Wilcox

Frank B Dean

Shashi Gupta

David Lehmann

Deborah Ayers

Michael Lochrie

Glenn Sanders

David Sterling

Michael Riel-Mehan

Anne Baumstummler

Garry Dallmann

Stacie Bell

Frederic Marc-Kreucher

Vladimir Kery

Ross Rabin

Masao Hirota

Dominic A Zichi

Tomoki Suzuki

Jeffrey P Davis

Yuichi Ishikawa

Ikuo Murakami

Sheri Wilcox

Penelope J Toothman

Steven Ringquist

Amy Gelinas

Nikos Pagratis

Thale C Jarvis

Frédéric Marc-Kreucher

Diane Tassett

Urs A Ochsner

Polynucleotides, such as aptamers, comprising at least first one 5-position modified pyrimidine and at least one second 5-position modified pyrimidine are provided, wherein the first and second 5-position modified pyrimidines are different. Methods of selecting and using such polynucleotides, such as aptamers, are also provided.

Oligonucleotides comprising modified nucleosides

Described herein are aptamers capable of binding to growth differentiation factor 11 (GDF11) protein; compositions comprising a GDF11 binding aptamer with a GDF11 protein; and methods of making and using the same.

Nucleic acid compounds for binding growth differentiation factor 11

The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 18, Table 20, or Table 21, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.

Lung cancer biomarkers and uses thereof

Aptamers that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs.

Post-selex modification methods

Aptamers having improved stability against nucleases that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs.

PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders

Described herein are compositions and methods for detecting the presence or absence of a microorganism in a sample comprising contacting the sample with an aptamer capable of binding to a cell-surface protein of the microorganism to form a complex, contacting the mixture with a second aptamer capable of binding to the first cell-surface protein or a second cell-surface protein of the microorganism; and performing an assay to detect the second aptamer, wherein detecting the second aptamer indicates that the microorganism is present in the sample, and wherein not detecting the second aptamer indicates that the microorganism is absent from the sample.

Compositions and methods for detecting microorganisms

The present invention relates to a method of detecting a microorganism, in particular, in a sample, comprising the steps of a) incubating the sample with a slow off-rate modified aptamer (SOMAmer) comprising a fluorescent label, b) optionally washing the sample, c) analyzing the sample by a fluorescence-based detection method. The invention further relates to a slow off-rate modified aptamer comprising a fluorescent label, wherein the SOMAmer comprises a nucleotide sequence specific for, its use for detectingcells in a sample, and to a microarray or biosensor and a kit comprising at least one of such SOMAmers comprising a fluorescent label.

Method of detecting a microorganism in a sample by a fluorescence based detection method

The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection, treatment and diagnosis of tuberculosis (TB). In one aspect, the present application includes the identification of biomarkers that can be used alone or in various combinations for the detection of TB, including those set forth in Tables 1, 2, 4, 5, and 8 to 12. In another aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose or prognose TB or follow treatment response. In another aspect, methods are provided for diagnosing TB in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Tables 1, 2, 4, 5, and 8 to 12, wherein the individual is classified as having TB, or the likelihood of the individual having TB is determined, based on the at least one biomarker value.

Tuberculosis biomarkers and uses thereof

Described herein are compositions comprising a first aptamer, second aptamer and a target that are capable of forming a ternary complex, and wherein the first aptamer and the second aptamer comprise C-5 pyrimidine modification schemes that are different, and methods of making and using such compositions.

Multiaptamer target detection

Described herein are aptamers capable of binding to growth differentiation factor 8 (GDF8) protein; compositions comprising a GDF8 binding aptamer; and methods of making and using the same.

Nucleic acid compounds for binding growth differentiation factor 8

Described herein are 5-position modified cytosine nucleotides and nucleosides as well as phosphoramidites and triphosphates derivatives thereof. Further provided are methods of making and using the same, and compositions and uses of the modified nucleosides as part of a nucleic acid molecule (e.g., aptamer).

Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto

The present disclosure relates to the field of nucleic acid chemistry, specifically to 5-position modified uridines as well as phosphoramidite and triphosphate derivatives thereof. The present disclosure also relates to methods of making and using the same.

5-position modified pyrimidines and their use

Growing community of inventors

Boulder, CO, United States of America

Nebojsa Janjic